Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Sarepta Therapeutics, Inc. Develops precision genetic medicines for rare neuromuscular disorders.	United States of America	SRPT
Savara Inc Clinical-stage biopharma developing inhaled therapies for rare respiratory diseases.	United States of America	SVRA
SAWAI GROUP HOLDINGS Co., Ltd. A leading Japanese generic drug maker expanding into digital health and wellness solutions.	Japan	4887
Scandion Oncology A/S Biotech company in liquidation, formerly developing therapies to overcome cancer drug resistance.	Denmark	SCOL
Scholar Rock Holding Corp Biopharma developing medicines for neuromuscular diseases by targeting protein growth factors.	United States of America	SRRK
Scienture Holdings, Inc. Develops and commercializes specialty drugs for unmet medical needs, focusing on CNS disorders.	United States of America	SCNX
Scilex Holding Co Develops and commercializes non-opioid products for acute and chronic pain management.	United States of America	SCLX
Scinai Immunotherapeutics Ltd. Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.	United States of America	SCNI
SciSparc Ltd. Developing cannabinoid-based therapies for central nervous system (CNS) disorders.	United States of America	SPRC
SCM Lifescience Co., Ltd. Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.	South Korea	298060